TAOX
TAO Synergies Inc.NASDAQHealthcare$5.94+4.21%ClosedMarket Cap: $19.5M
As of 2026-04-07
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
0.50
P/S
65.27
EV/EBITDA
-1.55
DCF Value
—
FCF Yield
-32.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
100.0%
Operating Margin
-3025.2%
Net Margin
-9609.2%
ROE
-182.5%
ROA
-111.2%
ROIC
-37.7%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $203.4K | $-3.9M | $-1.56 |
| Q2 2025 | $4.0K | $-17.5M | $-11.26 |
| Q1 2025 | $0.00 | $385.2K | $0.12 |
| Q4 2024 | $0.00 | $-5.5M | $-4.18 |
Trading Activity
Insider Trades
View AllTUCHMAN ALAN Jdirector, officer: Chief Medical Officer
SellThu Feb 05
WEINSTEIN ROBERTofficer: Chief Financial Officer
SellFri Oct 17
WEINSTEIN ROBERTofficer: Chief Financial Officer
SellFri Oct 17
WEINSTEIN ROBERTofficer: Chief Financial Officer
SellFri Oct 17
Singer William S.director
SellFri Oct 17
Company Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
2.04
Clinical-stage biopharmaceutical company developing a bryostatin‑1 platform for Alzheimer’s and other neurodegenerative/cognitive diseases. Also pivoting to a digital-asset treasury strategy focused on acquiring and staking TAO cryptocurrency.